title: Biology and therapeutic advances for pediatric osteosarcoma.
abstract: Osteosarcoma is the most common malignant bone tumor in children and adolescents. Survival for these patients was poor with the use of surgery and/or radiotherapy. The introduction of multi-agent chemotherapy dramatically improved the outcome for these patients and the majority of modern series report 3-year disease-free survival of 60%-70%. This paper describes current strategies for treating patients with osteosarcoma as well as review of the clinical features, radiologic and diagnostic work-up, and pathology. The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development. Therapy-related sequelae and future directions in the biology and therapy for these patients are also discussed.
authors.affiliation: Department of Pediatrics, Division of Hematology-Oncology, Stanford University Medical Center, Stanford, California 94305-5208, USA. Neyssa.marina@stanford.edu
authors.forename: Neyssa
authors.initials: N
authors.lastname: Marina
authors.forename: Mark
authors.initials: M
authors.lastname: Gebhardt
authors.forename: Lisa
authors.initials: L
authors.lastname: Teot
authors.forename: Richard
authors.initials: R
authors.lastname: Gorlick
mesh_terms: D001859:Bone Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D010372:Pediatrics; D011379:Prognosis